17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685

PRESS RELEASE

Sun Pharma announces USFDA tentative approval for generic Razadyne ™ Tablets

Mumbai, August 30, 2007: Sun Pharmaceutical Industries Ltd. announced that USFDA has granted tentative approval for the company's Abbreviated New Drug Application (ANDA) for generic Razadyne ™, galantamine tablets.

Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

These generic versions of galantamine are bio-equivalent to Razadyne ™ distributed by Ortho-McNeil Neurologics, Inc. The ANDA includes three strengths: tablets containing galantamine hydrobromide equivalent to 4mg, 8 mg and 12 mg base.

These strengths of branded galantamine have annual sales of approximately USD 120 million in the US.

Razadyne ™ is a trademark of Johnson & Johnson.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail miradesai@sunpharma.com